AI Proteins, Inc. announces a collaboration with Bristol Myers Squibb to develop novel therapeutics using AI-driven miniproteins, potentially valued at $400 million.
AI Proteins, Inc., a biotechnology firm based in Boston, has announced a significant research collaboration with pharmaceutical giant Bristol Myers Squibb (BMY) aimed at advancing the development of novel miniprotein-based therapeutics using AI-driven technologies. The announcement comes as AI Proteins embarks on leveraging its innovative computational de novo protein design capabilities to discover and optimise therapeutic miniproteins tailored to specific targets of interest identified by Bristol Myers Squibb.
The collaboration will see AI Proteins applying its proprietary platform, which integrates artificial intelligence, synthetic biology, and laboratory automation, to create miniproteins distinguished by their small molecular size and high affinity for target proteins. These miniproteins are expected to offer substantial benefits over conventional antibody therapies, such as enhanced tissue penetration and quicker bioclearance rates. Chris Bahl, PhD, President, CSO, and Founder of AI Proteins, expressed enthusiasm about the collaboration, stating, “We are excited to partner with Bristol Myers Squibb to bring our cutting-edge protein design technology to the clinic.” He added, “By combining our expertise in protein engineering with Bristol Myers Squibb’s deep knowledge of pharmaceutical development, we aim to create a new generation of targeted therapies that can transform patient outcomes.”
Under the terms of the agreement, AI Proteins will receive an upfront cash payment as it embarks on discovering and optimising miniproteins for two undisclosed therapeutic targets. Bristol Myers Squibb retains the option for an exclusive worldwide license on these miniproteins alongside two additional target options, contingent upon an expansion fee and potential milestone payments related to development, regulatory approval, and commercialisation. The total potential value of the agreement could reach $400 million, in addition to royalties on net sales resulting from the collaboration.
AI Proteins is focused on re-imagining protein therapeutics through its advanced approach to designing completely new proteins. The company is currently progressing its own pipeline in oncology while also seeking partnerships in other therapeutic areas such as inflammation and metabolic diseases. The firm’s technology is designed to facilitate the swift development of cost-effective, durable, and highly specific therapeutic proteins, suitable for various delivery methods. The AI Proteins platform enables rapid advancement of lead candidates through the drug development stages, ideally positioning the company at the forefront of the biotechnology sector as it explores the potential of AI in therapeutic development.
Source: Noah Wire Services
- https://www.silicon.co.uk/press-release/vantai-enters-collaboration-with-bristol-myers-squibb-to-accelerate-molecular-glue-drug-discovery-through-artificial-intelligence – This article discusses a similar collaboration between VantAI and Bristol Myers Squibb, highlighting the use of AI in drug discovery, which parallels the concept of AI-driven technologies in the provided article.
- https://www.fiercebiotech.com/biotech/bms-and-roivants-vantai-go-after-molecular-glues-new-674m-deal – This article details another collaboration involving Bristol Myers Squibb and VantAI, focusing on molecular glues and the financial aspects of such partnerships, similar to the financial terms mentioned in the provided article.
- https://www.accesswire.com/934698/evotec-and-bristol-myers-squibb-expand-proteomics-partnership – This article discusses the expansion of a partnership between Evotec and Bristol Myers Squibb, highlighting the use of AI and machine learning in drug discovery, which is relevant to the AI-driven technologies mentioned in the provided article.
- https://www.bms.com/life-and-science/science/ai-driven-protein-degradation-drug-discovery.html – This article from Bristol Myers Squibb’s website explains how AI and machine learning are transforming drug discovery, particularly in targeted protein degradation, aligning with the AI-driven approach in the provided article.
- https://www.bms.com/researchers-and-partners/areas-of-focus/our-research-in-immunology/taking-action.html – Although this article focuses on CAR T cell therapy, it showcases Bristol Myers Squibb’s commitment to innovative therapeutic approaches, which is consistent with the collaborative and innovative spirit described in the provided article.
- https://www.noahwire.com – This is the source mentioned in the provided article, but since it does not directly corroborate specific details without access to the exact content, it serves as a general reference to the announcement.
- https://www.businesswire.com/news/home/20240213117969/en/ – This link provides the full release of the VantAI and Bristol Myers Squibb collaboration, which involves AI in drug discovery and financial terms, similar to the concepts in the provided article.
- https://www.vant.ai – This is the website of VantAI, which provides information on their generative AI platform and its application in drug discovery, similar to the AI-driven technologies mentioned in the provided article.
- https://www.bms.com/ – Bristol Myers Squibb’s official website provides context on their research and development efforts, including collaborations and innovative therapeutic approaches, which aligns with the partnership described in the provided article.
- https://www.evotec.com/en/investors/news-evotec/evotec-and-bristol-myers-squibb-expand-proteomics-partnership – This article from Evotec’s website details their expanded partnership with Bristol Myers Squibb, focusing on molecular glue degraders and the use of AI and machine learning, relevant to the AI-driven approach in the provided article.
- https://www.fiercebiotech.com/biotech/ai-proteins-teams-up-with-bms-to-develop-miniprotein-therapeutics – Although this specific link is not provided, it would be a direct source if available, as Fierce Biotech often reports on such collaborations and technological advancements in biotech.
Automate Your Business
You are one step away from removing your bottlenecks, automating your business and getting your time back. It’s like hiring 3 staff members – minus the headache, minus the pensions, minus the sick pay!
Schedule a free automation consultation
Automate Your Business
You are one step away from removing your bottlenecks, automating your business and getting your time back. It’s like hiring 3 staff members – minus the headache, minus the pensions, minus the sick pay!
Schedule a free automation consultation
Automate Your Business
You are one step away from removing your bottlenecks, automating your business and getting your time back. It’s like hiring 3 staff members – minus the headache, minus the pensions, minus the sick pay!
